Categories
Change Password!
Reset Password!
Taking NSAIDs after 60? Study warns of increased G...
Low-dose aspirin raises gastric and duodenal ulcer...
A large population-based analysis of over 220,000 volunteers has revealed that low-dose aspirin initiation is connected with increased risk of ga...
Tegoprazan emerges as fast-acting alternative to P...
A large study has positioned tegoprazan, a potassium-competitive acid blocker (PCAB), as a next-generation therapy for gastroesophageal reflux di...
Global PPI use hits 25%: Study flags rising long-t...
A large-scale systematic review assessing global trends in proton pump inhibitor (PPI) use has revealed that these acid-suppressing drugs are use...
Updated clinical guidance highlights optimal treat...
Helicobacter pylori (H. pylori) infection remains one of the most common chronic bacterial infections worldwide and is a major contributor to dys...
Tradipitant
Tradipitant is a centrally acting antiemetic approved by the Food and Drug Administration (FDA) on 30 December 2025 for the prevention of motion...
High-dose vs. conventional therapy for H. pylori e...
Optimizing Helicobacter pylori (H. pylori) eradication therapy is fundamental in the era of rising antibiotic resistance.
Multi-strain probiotics as nutritional therapy for...
Chronic constipation is a common gastrointestinal disorder among middle-aged and older adults, often linked with reduced quality of life and limi...
Omeprazole–domperidone combination delivers signif...
Acid peptic disease (APD) continues to impose a considerable gastrointestinal burden on patients with Type 2 diabetes mellitus (T2DM), with sympt...
Fidaxomicin
Fidaxomicin is a novel macrocyclic macrolide antibiotic and the first member of a new class of antimicrobial agents.
